EGFR and adenocarcinoma: The HR for 1‐year PFS for receiving erlotinib was 1.15 (1.09–1.21) in the whole cohort, 1.11 (1.03–1.17) in the EGFR‐TKI responders, 1.16 (1.08–1.25) in the adherent subgroup, 1.35 (1.24–1.47) in the adenocarcinoma subgroup, and 1.39 (1.22–1.59) in the adenocarcinoma with second‐line TKIs subgroup.